1. Known anaphylaxis to any of the trial vaccine components (including excipients of the trial vaccines) or drugs. 2. Participants with previous documented SARS-CoV-2 infection by history obtained from participant(s) or parent(s). 3. Receipt of immunoglobulins or blood products within 3 months of vaccination. 4. Receipt of any other vaccines within 14 days (for inactivated vaccines, not include influenza vaccine) or 28 days (for live vaccines) prior to enrollment in this trial. 5. Use of or anticipated need to use, within the next 6 months of any medications that may be associated with impaired immune responsiveness or with immunosuppression. Presence of any acute illness required medical attention within 14 days of vaccination.

1. Known anaphylaxis to any of the trial vaccine components (including excipients of the trial vaccines) or drugs. 2. Participants with previous documented SARS-CoV-2 infection by history obtained from participant(s) or parent(s). 3. Receipt of immunoglobulins or blood products within 3 months of vaccination. 4. Receipt of any other vaccines within 14 days (for inactivated vaccines, not include influenza vaccine) or 28 days (for live vaccines) prior to enrollment in this trial. 5. Use of or anticipated need to use, within the next 6 months of any medications that may be associated with impaired immune responsiveness or with immunosuppression. Presence of any acute illness required medical attention within 14 days of vaccination.